Overview

PRE-I-SPY Phase I/Ib Program

Status:
Recruiting

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Phase:

Phase 1

Details

Lead Sponsor:

QuantumLeap Healthcare Collaborative

Treatments:

Trastuzumab
Trastuzumab deruxtecan